Eli Lilly’s novel oral weight loss medication, Foundayo (orforglipron), has demonstrated significant efficacy in patients aged 65 and older, achieving up to a 13% reduction in body weight in a post-hoc analysis of Phase III trials. This development arrives as the weight loss drug market continues its rapid expansion, fueled by the success of GLP-1 receptor agonists and intense competition between pharmaceutical giants like Lilly and Novo Nordisk.
The encouraging data, unveiled at the European Congress on Obesity (ECO) 2026 in Istanbul, Turkey, underscores the potential of Foundayo to address the complex needs of weight management in an aging population. The findings from the ATTAIN-1 and ATTAIN-2 trials indicate that the oral GLP-1 receptor agonist can deliver clinically meaningful weight loss in older adults with obesity or overweight, irrespective of their type 2 diabetes status, while maintaining a favorable safety profile.
This latest stride by Lilly positions Foundayo as a significant contender in a market increasingly dominated by injectables, but now seeing a surge in oral alternatives. The approval timelines for these groundbreaking medications highlight a rapid pace of innovation and market entry, setting the stage for a dynamic and highly competitive landscape in the coming years.
A Timeline of Innovation: The Race for Oral Weight Loss Dominance
The journey to bring effective oral weight loss medications to patients has been a swift and impactful one. Eli Lilly’s Foundayo received its crucial marketing authorization on April 1, 2026. This followed closely on the heels of a major regulatory win for competitor Novo Nordisk, whose oral formulation of Wegovy (semaglutide) secured approval from the U.S. Food and Drug Administration (FDA) in late December 2025, with a subsequent market launch in January 2026.
This close proximity in regulatory approvals underscores the intense research and development efforts within the pharmaceutical sector to capture a significant share of the burgeoning obesity market. Lilly’s April 2026 approval for Foundayo, just three months after Novo Nordisk’s oral Wegovy, signals a direct and accelerated competitive response, demonstrating the strategic importance of oral delivery systems in this therapeutic area.
The initial market reception for both medications has been robust, hinting at the substantial unmet need for accessible and effective weight management solutions. Novo Nordisk reported an impressive surge in prescriptions for oral Wegovy, exceeding 200,000 weekly in the week ending April 17, 2026. The drug’s first quarter (Q1) of 2026 saw a total of 1.3 million prescriptions, climbing to over two million since its launch. This translated into a substantial DKr2.3 billion (approximately $360 million) in quarterly revenue for oral Wegovy, a testament to its strong early market performance.
Eli Lilly’s launch, while occurring slightly later in the quarter, also demonstrated promising early traction. In its third week on the market, ending April 24, 2026, Foundayo saw approximately 5,600 prescriptions. While these initial figures are lower than Novo Nordisk’s, they represent a strong opening for a new entrant, particularly considering the short period of market availability within Q1.
Foundayo’s Efficacy in Older Adults: Key Data from ATTAIN Trials
The ATTAIN-1 and ATTAIN-2 trials, pivotal in establishing Foundayo’s efficacy and safety, focused on adults aged 65 and older who were classified as having obesity or overweight. These trials were designed to assess the impact of different dosages of orforglipron on body weight reduction, with careful attention to the specific needs and potential vulnerabilities of the geriatric population.
ATTAIN-1: Addressing Obesity Without Type 2 Diabetes
In the ATTAIN-1 trial, which specifically enrolled participants with obesity or overweight but without type 2 diabetes, the highest dose of orforglipron (17.2mg) yielded a mean body weight reduction of 13% in the observed data for individuals aged 65 and older. This significant outcome suggests a potent effect of the drug in this demographic.
Further stratification of the data within ATTAIN-1 revealed a dose-dependent response:
- Low-dose cohort (5.5mg): Patients in this group experienced a mean body weight reduction of 7.9%.
- Medium-dose cohort (9mg): This group achieved a mean body weight reduction of 11.3%.
- Placebo group: In stark contrast, the placebo group saw a minimal mean body weight reduction of 1.6%.
These results highlight a clear and statistically significant difference in weight loss between the active treatment groups and the placebo, with higher doses correlating to greater efficacy.
ATTAIN-2: Targeting Obesity with Type 2 Diabetes
The ATTAIN-2 trial expanded the scope to include patients with obesity or overweight who also had type 2 diabetes. This subgroup often presents additional challenges in weight management due to metabolic complexities. The findings from ATTAIN-2 were equally compelling:
- High-dose cohort (17.2mg): Participants in this group achieved a mean weight loss reduction of 12.2%.
- Low-dose cohort (5.5mg): This cohort observed a mean weight loss of 7.5%.
- Medium-dose cohort (9mg): Patients in this group experienced a mean weight loss of 8.3%.
- Placebo group: The placebo group in ATTAIN-2 showed a mean weight loss of 2.3%.
The data from ATTAIN-2 further reinforces Foundayo’s effectiveness in promoting weight loss, even in the presence of type 2 diabetes. The observed weight reductions across all active treatment arms significantly outperformed the placebo, indicating the drug’s therapeutic value for this complex patient population.
The presentation of these findings at ECO 2026, a premier international congress for obesity research, underscores their significance and the scientific community’s interest in these advancements. The credit for the visual representation of these advancements goes to Michael Siluk of UCG/Universal Images Group via Getty Images, capturing the essence of this pivotal moment in obesity treatment research.
Expert Endorsements: A Focus on Benefit and Risk in Older Adults
The positive results from the ATTAIN trials have garnered enthusiastic support from key opinion leaders within the pharmaceutical industry. Dr. Rachel Batterham, Senior Vice President of Medical Innovation and External Engagement at Lilly Cardiometabolic Health, expressed considerable optimism regarding Foundayo’s performance, particularly within the older adult demographic.
"Weight management in older adults requires careful consideration of both benefit and risk," Dr. Batterham stated. "These data are reassuring on both fronts – up to 13% weight loss was observed in patients 65 and older taking Foundayo, with a safety profile similar to what was observed in the broader trial populations."
Her emphasis on a "reassuring" safety profile is critical, as older adults can be more susceptible to adverse events due to age-related physiological changes and the potential for polypharmacy. The similarity in safety outcomes to broader trial populations suggests that Foundayo’s tolerability is maintained even in this specific age group.
Dr. Batterham also highlighted the practical advantages of an oral formulation for this demographic. "The fact that these results were achieved with a once-daily pill that patients can take at any time, without planning around meals or dealing with injections, matters in this age group," she added. This convenience factor is a significant differentiator, addressing potential barriers to adherence such as needle phobia, the need for refrigeration, or the inconvenience of coordinating medication timing with meals, which can be particularly burdensome for older individuals.
Foundayo’s unique characteristic of being the only approved glucagon-like peptide-1 receptor agonist (GLP-1RA) pill that can be taken at any time of day without food or water restrictions further amplifies its appeal. This "take-anytime" flexibility removes a common constraint associated with oral GLP-1RAs and injectables, potentially enhancing patient compliance and overall treatment success.
The Evolving GLP-1 Market Landscape: Projections and Competition
The GLP-1 receptor agonist market is on an unprecedented growth trajectory, with significant future sales projected by industry analysts. GlobalData, a leading data and analytics company and the parent of Clinical Trials Arena, has forecasted substantial revenue for orforglipron. Their consensus projected global sales of $14.36 billion for orforglipron by 2031.
This optimistic outlook is mirrored in broader market predictions. Sales in the GLP-1RA pill market are anticipated to reach a staggering $34.3 billion by 2031, according to GlobalData’s Pharmaceutical Intelligence Center. This forecast underscores the transformative impact of GLP-1RAs on the treatment of obesity and related metabolic conditions.
The intense competition between Eli Lilly and Novo Nordisk is a defining feature of this dynamic market. While Novo Nordisk secured the first-to-market advantage with its oral Wegovy, Lilly’s Foundayo is poised to capture a significant share with its distinct advantages, particularly its oral formulation and "take-anytime" flexibility.
The strategic implications of these developments are profound. Both companies are investing heavily in expanding manufacturing capacity and exploring new indications for their GLP-1RA drugs. The market is likely to see further innovation, including combination therapies and potentially even more targeted formulations for specific patient subgroups.
The presence of multiple effective oral GLP-1RA options, such as Foundayo, promises to broaden access to weight management treatments, moving beyond injectable-only options. This increased accessibility could lead to a wider patient population benefiting from these groundbreaking therapies, ultimately contributing to improved public health outcomes related to obesity and its associated comorbidities. The ongoing advancements in this field are not just about pharmaceutical sales; they represent a significant shift in how chronic diseases like obesity are managed, offering hope and tangible solutions to millions worldwide.
About the Author
